drugset
drugset / Trial / NCT06883695

A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

NCT06883695 ↗

Phase 1 Completed 40 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3045 in healthy subjects.

Timeline

Start
2025-04-08
Primary completion
2025-06-17
Completion
2025-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-3045 Unknown — —

Indications

rheumatoid arthritis